Alivus Life Sciences Limited — Q4 FY26
Alivus Life Sciences delivered a strong Q4 FY26 with revenue of 689 crore (+6.1% YoY) and EBITDA margin of 34.4% (+230 bps YoY), driven by favorable product mix, cost discipline...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
EBITDA margin guidance raised to 30-32%
EBITDA margin expected to be in 30-32% range going forward, up from earlier guidance of 28-30%.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY26
CDMO: 1-2 new projects expected by Q1 FY27
Management expects to conclude 1-2 new CDMO projects by Q1 FY27, with early quantities already supplied.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1